In addition, the first reported pan-Raf inhibitor BAY43-996 (Sorafenib 1), showed weak efficacy in patients with B-Raf mutation (V600E)-based melanoma (Smith et al. 2001; Khire et al. 2004; Ramurthy et al. 2008). Here, BRAF is linked to melanoma.